UNSPSC 51393000: Sympathomimetic or adrenergic quinazolines

This classification denotes Sympathomimetic or adrenergic drugs made from benzopyrimidines, or compounds consisting of two six-membered rings, one benzene, one pyrimidine ring.

UNSPSC 51393000 Sympathomimetic or adrenergic quinazolines (Class) shows limited alignment between its nominal pharmaceutical scope and recent state and local procurement activity. The code's abstract name refers to a narrow class of chemical compounds, but the recent opportunities posted under it reflect broader pharmaceutical supply and pharmacy benefit program modernization work. Seminole County, Florida issued an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, representing emergency response and public health procurement rather than adrenergic compounds specifically. The Texas Health and Human Services Commission posted an RFI on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels—a strategic sourcing and program design exercise unrelated to the code's stated chemical category. County health departments and state HHS commissions appear as issuing bodies, but the source contains no evidence of repeat buyers or sustained procurement activity under this code.

Recent activity is concentrated in Texas and Florida, with no additional jurisdictions represented in the available records. The Seminole County IFB (IFB60459723LAS) required electronic bid submission with a response deadline of July 26, 2023, and specified quarterly delivery to the Seminole County Community Health Building in Sanford; the contract carried a two-year initial term with a one-year renewal option and was potentially funded through FEMA. The Texas HHS RFI (HHS0017013) functioned as market research rather than a binding solicitation, with no award value, set-aside designations, or formal evaluation criteria. The mismatch between the code's pharmaceutical chemistry definition and the actual work being procured—naloxone distribution systems and pharmacy program redesign—suggests this code may be mistagged in state procurement systems, and the limited recent-opportunity record offers little basis for pursuing activity under it without clarity on true category intent.